• search hit 1 of 1
Back to Result List

European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications

Please always quote using this URN: urn:nbn:de:bvb:20-opus-141913
  • The European Myeloma Network provides recommendations for the management of the most common complications of multiple myeloma. Whole body low-dose computed tomography is more sensitive than conventional radiography in depicting osteolytic disease and thus we recommend it as the novel standard for the detection of lytic lesions in myeloma (grade 1A). Myeloma patients with adequate renal function and bone disease at diagnosis should be treated with zoledronic acid or pamidronate (grade 1A). Symptomatic patients without lytic lesions onThe European Myeloma Network provides recommendations for the management of the most common complications of multiple myeloma. Whole body low-dose computed tomography is more sensitive than conventional radiography in depicting osteolytic disease and thus we recommend it as the novel standard for the detection of lytic lesions in myeloma (grade 1A). Myeloma patients with adequate renal function and bone disease at diagnosis should be treated with zoledronic acid or pamidronate (grade 1A). Symptomatic patients without lytic lesions on conventional radiography can be treated with zoledronic acid (grade 1B), but its advantage is not clear for patients with no bone involvement on computed tomography or magnetic resonance imaging. In asymptomatic myeloma, bisphosphonates are not recommended (grade 1A). Zoledronic acid should be given continuously, but it is not clear if patients who achieve at least a very good partial response benefit from its continuous use (grade 1B). Treatment with erythropoietic-stimulating agents may be initiated in patients with persistent symptomatic anemia (hemoglobin < 10g/dL) in whom other causes of anemia have been excluded (grade 1B). Erythropoietic agents should be stopped after 6-8 weeks if no adequate hemoglobin response is achieved. For renal impairment, bortezomib-based regimens are the current standard of care (grade 1A). For the management of treatment-induced peripheral neuropathy, drug modification is needed (grade 1C). Vaccination against influenza is recommended; vaccination against streptococcus pneumonia and hemophilus influenza is appropriate, but efficacy is not guaranteed due to suboptimal immune response (grade 1C). Prophylactic aciclovir (or valacyclovir) is recommended for patients receiving proteasome inhibitors, autologous or allogeneic transplantation (grade 1A).show moreshow less

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar Statistics
Metadaten
Author: Evangelos Terpos, Martina Kleber, Monika Engelhardt, Sonja Zweegman, Francesca Gay, Efstathios Kastritis, Niels W. C. J. van de Donk, Benedetto Bruno, Orhan Sezer, Annemiek Broijl, Sara Bringhen, Meral Beksac, Alessandra Larocca, Roman Hajek, Pellegrino Musto, Hans Erik Johnsen, Fortunato Morabito, Heinz Ludwig, Michele Cavo, Hermann Einsele, Pieter Sonneveld, Meletios A. Dimopoulos, Antonio Palumbo
URN:urn:nbn:de:bvb:20-opus-141913
Document Type:Journal article
Faculties:Medizinische Fakultät / Medizinische Klinik und Poliklinik II
Language:English
Parent Title (English):Haematologica
Year of Completion:2015
Volume:100
Issue:10
Source:Haematologica 2015; 100(10), pp. 1254-1266. doi:10.3324/haematol.2014.117176
DOI:https://doi.org/10.3324/haematol.2014.117176
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Tag:acute kidney injury; bone-disease; enal impairment; erythropoiesis-stimulating agents; group consensus statement; newly-diagnosed myeloma; randomized controlled trial; recombinant-human-erythropoietin; stem-cell transplantation; zoledonic acid
Release Date:2016/12/16
Contributing Corporation:European Myeloma Network
First Page:1254
Last Page:1266
Licence (German):License LogoDeutsches Urheberrecht